Barclays maintains Pacific Biosciences at Underweight, raises price target to $2 from $1.25

Barclays kept its Underweight rating on Pacific Biosciences but raised its price target to $2 from $1.25, suggesting a 21.6% downside from the last close of $2.55. The increase represents a 60.0% rise in the target price.

Original reporting
Published Nov 5, 2026, 6:59 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 7:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Barclays maintains Pacific Biosciences at Underweight, raises price target to $2 from $1.25 — source image
Decision brief

The 30-second read

$PACBBearishMed
01

Why it matters

The downgrade could trigger short covering or further downside if investors align with the new target.

02

Market read

Analyst target change is the primary catalyst, likely influencing short-term price action.

03

What to watch

Potential upcoming data releases or partnership announcements could offset the bearish target.

Relevance 6/10Novelty 6/10Timing: after market close

Background

Barclays' research note updates its valuation for Pacific Biosciences, a small-cap biotech focused on DNA sequencing technology.

Company-level read

Ticker impact

$PACBBearishHigh confidence
Context

Barclays raised its price target for Pacific Biosciences to $2 from $1.25, implying a downside from the current price.

Expected impact

likely pressure as the market prices in the lower target

Evidence & confidence

The new target is below the recent close, indicating a bearish view from a major broker.

Market effects

May affect sentiment in the biotech sequencing sector.

Limited to US biotech investors.

Low

Counterpoint

Some investors may view the target raise as a buying opportunity if they believe the market overreacted to recent volatility.

Key entities

  • Barclays

    Equity research firm providing the price target update.

  • Pacific Biosciences

    US-listed biotech company (ticker PACB).

Related articles

$PACBMed

Pacific Biosciences of California Inc (PACB) (Q3 2026) Earnings Call Highlights: Revenue

Pacific Biosciences (PACB) reported Q3 2026 revenue growth of 6% YoY to $40.6M, with consumables revenue down 2% YoY. Non-GAAP gross margin fell to 36% from 42% due to higher costs. Americas and Asia Pacific revenues declined, while EMEA grew 30%. Cash burn was $32.8M, with Q4 expected to decrease. The company narrowed full-year revenue guidance to $155M-$160M and expects cash flow breakeven in 2028.

$PACBHighAI 8/10

What Pacific Biosciences of California (PACB) Said on Its Q3 Earnings Call

Pacific Biosciences (PACB) reported Q3 earnings, with Revio consumables pull-through at $204,000 per system. Instrument revenue rose to $13.2M, with 15 Revio and 35 Vega systems sold. Clinical business grew over 20% YoY, now exceeding 20% of total business. Non-GAAP net loss narrowed to $32.8M, with cash at $199.4M. The company maintained its 2026 outlook and expects cash flow breakeven in 2028.

$PACBMed

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB): PacBio Announces Third Quarter 2026 Financial Results

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PacBio Announces Third Quarter 2026 Financial Results MENLO PARK, Calif., November 4, 2026 (GLOBE NEWSWIRE) – PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2026. Recent Business Highlights • Delivered total revenue of $40

$PACBMed

Why PacBio (PACB) Stock Is Trading Up Today

Pacific Biosciences of California (PACB) shares rose 15% to $2.88 after EpiSign and Geneyx announced a partnership using PacBio's HiFi sequencing for rare disease analysis. The stock is up 56.5% year-to-date, reaching a 52-week high. PacBio's shares are volatile, with 87 moves over 5% in the past year.